Condition
Intermediate Risk Acute Myeloid Leukemia clinical trials and research
As of November 12, 2026, Find a Trial lists 3 Intermediate Risk Acute Myeloid Leukemia clinical trials that are recruiting, in China. By phase: Phase 2 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 3Clinical trials
- 1Country
Newest Intermediate Risk Acute Myeloid Leukemia clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Venetoclax and Azacitidine Consolidation After Remission in Intermediate-Risk AML | Phase 2 | Suzhou, Jiangsu | Recruiting | Jun 26, 2026 |
| Gilteritinib with Venetoclax and Azacitidine, then High‑Dose Cytarabine and Gilteritinib Maintenance for Newly Diagnosed FLT3‑ITD AML | Phase 2 | Hangzhou, Zhejiang | Recruiting | Dec 2, 2025 |
| Combining venetoclax and azacitidine with HAAG for treating newly diagnosed AML | Phase 2 | Suzhou, Jiangsu | Recruiting | May 1, 2024 |
All recruiting trials (3)
-
Venetoclax and Azacitidine Consolidation After Remission in Intermediate-Risk AML
We’re testing if a venetoclax-plus-azacitidine consolidation approach works as well as standard high-dose chemotherapy for adults with intermediate-risk AML who have already achieved remission and are headed to stem cell transplant.
-
Gilteritinib with Venetoclax and Azacitidine, then High‑Dose Cytarabine and Gilteritinib Maintenance for Newly Diagnosed FLT3‑ITD AML
This approach tests whether combining gilteritinib with venetoclax and azacitidine for induction, followed by DeepScan‑guided high‑dose cytarabine consolidation and gilteritinib maintenance, can produce deep remissions and allow fit adults with newly diagnosed FLT3‑ITD AML to avoid transplant.
-
Combining venetoclax and azacitidine with HAAG for treating newly diagnosed AML
This study is testing a new combination of medications for people who have just been diagnosed with intermediate and high-risk acute myeloid leukemia to see if it helps them respond better to treatment.
Related topics
Quick answers
How many Intermediate Risk Acute Myeloid Leukemia clinical trials are recruiting right now?
3, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.